|1.||Kuroda, Y: 3 articles (04/2002 - 06/2000)|
|2.||Sharifzadeh, Mohammad: 2 articles (08/2015 - 11/2011)|
|3.||Ghadiri, Tahereh: 2 articles (08/2015 - 11/2011)|
|4.||Lecanu, Laurent: 2 articles (01/2009 - 12/2003)|
|5.||Xu, Jing: 2 articles (01/2009 - 12/2003)|
|6.||Greeson, Janet: 2 articles (01/2009 - 12/2003)|
|7.||Papadopoulos, Vassilios: 2 articles (01/2009 - 12/2003)|
|8.||Tabernero, Arantxa: 2 articles (08/2006 - 03/2005)|
|9.||Medina, José M: 2 articles (08/2006 - 03/2005)|
|10.||Sánchez-Alvarez, Rosa: 2 articles (08/2006 - 03/2005)|
|1.||Acute Liver Failure (Fulminant Hepatic Failure)
11/01/1996 - "Protective effects of dibutyryl cyclic AMP on acute hepatic failure in rats."
11/01/1996 - "Therefore, treatment with DBcAMP suppressed acute hepatic failure induced by D-Gal and Et, resulting in a significant increase in the survival rate."
03/01/1989 - "On histological findings, inflammatory changes were observed in group I and focal necrosis in group II while liver degeneration with massive necrosis was seen in groups III and IV. In conclusion, acute liver failure induced by D-Gal was apparently protected by the administration of DBcAMP."
03/01/1989 - "[Protective effects of DBcAMP on acute liver failure induced by D-galactosamine in rats]."
07/01/1995 - "In conclusion, spleen had the positive effect for OK-432 treatment, and also had the negative effect for DBcAMP treatment on acute liver failure induced by D-Gal and Et."
11/01/1988 - "The results indicate that DBcAMP is useful for the treatment of congestive heart failure because it improves cardiac hemodynamics by afterload reduction and has a strong vasodilating effect on renal vascular beds."
10/01/1989 - "Effects of DBcAMP on exercise capacity in patients with and without chronic heart failure."
11/01/1988 - "Acute effects of dibutyryl cyclic AMP on renal circulation in congestive heart failure."
05/01/1983 - "Hemodynamic effects of dibutyryl cyclic AMP in congestive heart failure."
11/01/1982 - "Dibutyryl cyclic AMP was administered to 2 patients with severe congestive heart failure. "
01/01/1997 - "An ointment containing dibutyryl cyclic AMP has been used in the treatment of skin ulcers and found to be effective in promoting tissue repair. "
09/01/2000 - "We conclude that this series of stimulative actions on cytokine secretion, together with the facilitation of cell proliferation, contribute to the effects of DBcAMP on the healing of skin ulcers."
11/01/1995 - "It is appropriate to evaluate the bioavailability in damaged skin models for a drug, such as DBcAMP, which is used in the treatment of skin ulcer."
11/01/1995 - "Bucladesine, sodium N6,2'-O-dibutyryl cyclic 3',5' adenosine monophosphate (DBcAMP), which is effective for the treatment of chronic skin ulcers including decubitus ulcer, was evaluated for percutaneous absorption in rats with normal skin, stripped skin and full-thickness abrasion models. "
02/01/1988 - "Dibutyryl cyclic AMP modulation of gap junctions in SW-13 human adrenal cortical tumor cells."
08/01/1983 - "Tumor cells did not exhibit delta 4-desaturase activity, but such activity was restored in the C6 line upon dibutyryl cyclic AMP-induced differentiation. "
01/01/1979 - "Further, when the isolated adipose tissue cells were stimulated with dibutyryl cyclic AMP no difference was observed between the control and tumor bearing groups. "
03/01/1977 - "DBcAMP-treated tumor cells were marked by a proliferation of the Golgi complex and numerous vesicles containing fine granular material."
10/01/1976 - "In vivo, DBcAMP, Pap, and Theo caused a reduced tumor volume growth rate in animals with established tumors. "
|5.||Wounds and Injuries (Trauma)
03/01/2006 - "The wound-healing efficacy of the DBcAMP-incorporated dressing was evaluated on experimental full-thickness wounds in a rat model. "
03/01/2006 - "Data obtained in this study showed that the presence of DBcAMP accelerated healing and re-epithelialization of full-thickness wounds."
05/01/2006 - "Taken together, these results indicate that DBcAMP promotes neovascularization in wound healing, at least partly by increasing the accumulation of EPC at wound sites."
05/01/2006 - "EPC in DBcAMP-treated wounds were mainly localized to cell clusters at the border of the granulation tissue, a site where blood supply is most insufficient. "
05/01/2006 - "Topical application of DBcAMP resulted in significant acceleration of wound healing and wound vascularization partly via enhanced recruitment of EPC. "
|2.||Cyclic AMP (AMP, Cyclic)
|3.||Messenger RNA (mRNA)
|5.||Tretinoin (Retinoic Acid)
|6.||Adenosine Monophosphate (AMP)
|5.||Drug Therapy (Chemotherapy)